Digest Network Come funziona
Network
/
Società
Be
Non verificato

BeOne Medicines Ltd.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

26 comunicati stampa

Guarda tutti i comunicati
26/11/2025
Eventi
Industria
Oncologia
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Fonte
BeOne Medicines Ltd.
Emittente
Business Wire
1.00
0
20/11/2025
Biotecnologia
Farmaceutica
Salute
Oncologia
Eventi
Industria
BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
Fonte
BeOne Medicines Ltd.
Emittente
Business Wire
1.00
0
17/11/2025
Scienza
Medicina - Varie
Sanità
Biotecnologia
Farmaceutica
Salute
Oncologia
Industria
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
Fonte
BeOne Medicines Ltd.
Emittente
Business Wire
1.00
0
06/11/2025
Biotecnologia
Farmaceutica
Salute
Oncologia
Web e Social Network
Telefonia e Varie
Mercato azionario
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates
Fonte
BeOne Medicines Ltd.
Emittente
Business Wire
1.00
0
28/10/2025
Eventi
Web e Social Network
Scienza
Finanza
Associazioni/Professionisti
Biotecnologia
Sanità
Farmaceutica
Salute
Oncologia
BeOne Medicines to Present at Upcoming Investor Conferences
Fonte
BeOne Medicines Ltd.
Emittente
Business Wire
1.00
0
22/10/2025
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6
Fonte
BeOne Medicines Ltd.
Emittente
Business Wire
1.00
0
20/10/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Eventi
Industria
BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025
Fonte
BeOne Medicines Ltd.
Emittente
Business Wire
1.00
0
13/10/2025
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA
Fonte
BeOne Medicines Ltd.
Emittente
Business Wire
1.00
0
29/08/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Fonte
BeOne Medicines Ltd.
Emittente
Business Wire
1.00
0
27/08/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025
Fonte
BeOne Medicines Ltd.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0